Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Methods: Data from trials comparing E...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chee Khoon Lee, Lucy Davies, Yi Long Wu, Tetsuya Mitsudomi, Akira Inoue, Rafael Rosell, Caicun Zhou, Kazuhiko Nakagawa, Sumitra Thongprasert, Masahiro Fukuoka, Sally Lord, Ian Marschner, Yu Kang Tu, Richard J. Gralla, Val Gebski, Tony Mok, James Chih Hsin Yang
Format:	Journal
Published:	2018
Subjects:	Agricultural and Biological Sciences
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027265241&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/46393
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Lee C., et al.
Published: (2017)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
by: Wong, A.S., et al.
Published: (2014)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
by: Afrita Amalia Laitupa, -, et al.
Published: (2019)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Masahiro Fukuoka, et al.
Published: (2018)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
by: Chee Khoon Lee, et al.
Published: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
by: Chee Khoon Lee, et al.
Published: (2018)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
by: Voon, P.J., et al.
Published: (2014)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017)

Editorial: Update on Anti-EGFR therapy
by: Daniel Chua, et al.
Published: (2018)

Editorial: Update on Anti-EGFR therapy
by: Daniel Chua, et al.
Published: (2018)

PERBANDINGAN RESPONS TERAPI GEFITINIB PADA PASIEN KPKBSK DENGAN EGFR MUTASI EXON 19 DAN EXON 21
by: Titin Sholihah Agustina, NIM011180901
Published: (2017)

PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS DR SOETOMO SURABAYA
by: Afrita Amalia Laitupa
Published: (2019)

Erlotinib in previously treated non-small-cell lung cancer
by: Frances A. Shepherd, et al.
Published: (2018)

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
by: Giorgio V. Scagliotti, et al.
Published: (2018)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Wu Y., et al.
Published: (2017)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
by: Yi Long Wu, et al.
Published: (2018)

Lung cancer working group report
by: Nagahiro Saijo, et al.
Published: (2018)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
by: Reungwetwattana T.
Published: (2023)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
by: Cho B.C.
Published: (2023)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
by: Scagliotti G.V., et al.
Published: (2014)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
by: Chaichana Chantharakhit
Published: (2019)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
by: Sumitra Thongprasert, et al.
Published: (2018)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
by: Auliya Hafizah, Raysa

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert,S., et al.
Published: (2015)